Medical Condition

radiotherapy

Total Trials

9

Recruiting Now

9

Trial Phases

Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for radiotherapy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — radiotherapy Clinical Trials

How many clinical trials are currently recruiting for radiotherapy?

ClinicalMetric currently tracks 9 actively recruiting clinical trials for radiotherapy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for radiotherapy?

radiotherapy research spans Phase 2 (2 trials), Phase 3 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a radiotherapy clinical trial?

Eligibility criteria for radiotherapy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 2

Phase 3

Top Sponsors

Maria Sklodowska-Curie National Research Institute of Oncology 1 trial

Xinqiao Hospital of Chongqing 1 trial

Shandong Cancer Hospital and Institute 1 trial

Ontario Clinical Oncology Group (OCOG) 1 trial

Centre Francois Baclesse 1 trial

Recruiting Clinical Trials

NCT06201078 Phase 2

Recruiting

Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy

Maria Sklodowska-Curie Nationa...

View Trial →

NCT05754203

Recruiting

Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC

Xinqiao Hospital of Chongqing

View Trial →

NCT06841172 Phase 3

Recruiting

Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC

Shandong Cancer Hospital and I...

View Trial →

NCT05417516 Phase 3

Recruiting

A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)

Ontario Clinical Oncology Grou...

View Trial →

NCT04299646 Phase 2

Recruiting

A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases

Centre Francois Baclesse

View Trial →

NCT05514327

Recruiting

A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL

Peking Union Medical College H...

View Trial →

NCT06190782 Phase 3

Recruiting

Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma

Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites

Peking University Third Hospit...

View Trial →

Related Conditions

local recurrence of malignant tumor of prostate (1) lung cancer (1) immune checkpoint inhibitor (1) oligoprogressive metastatic disease (1) hepatocellular carcinoma hcc (1) systemic therapy (1) breast neoplasm female (1) cosmetic outcome (1) metastatic renal cell carcinoma (1) diffuse large b cell lymphoma (1) car t (1) bridging therapy (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology